Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% And 0.04% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis Of Dry Eye Disease And Experiencing An Episodic Flare Up
Conditions
Interventions
0.02% Betamethasone Sodium Phosphate
0.04% Betamethasone Sodium Phosphate
+1 more
Locations
28
United States
Trinity Research Group
Dothan, Alabama, United States
Canyon City EyeCare
Azusa, California, United States
North Valley Eye Medical Group, Inc.
Mission Hills, California, United States
LoBue Laser and Eye Medical Center
Murrieta, California, United States
Visionary Eye Institute
Newport Beach, California, United States
North Bay Eye Associates
Petaluma, California, United States
Start Date
January 7, 2021
Primary Completion Date
October 12, 2022
Completion Date
October 12, 2022
Last Updated
June 4, 2025
NCT07463950
NCT07363824
NCT07396441
NCT06841471
NCT07268599
NCT06064071
Lead Sponsor
Surface Ophthalmics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions